Addict Treatment Drug Buprenorphine Causing Many Unacknowledged Problems


Suboxone is the blockbuster drug most people have never heard of, says the New York Times. It generated $1.55 billion in U.S. sales last year, its success fueled by an exploding opioid abuse epidemic and the embrace of federal officials who helped finance its development and promoted it as a safer, less stigmatized alternative to methadone. More than a decade after Suboxone went on the market, and with the Affordable Care Act poised to bring many more addicts into treatment, the high hopes have been tempered by a messy reality, says the Times.

Suboxone’s parent drug buprenorphine has become both medication and dope: a treatment with successes and failures as well as a street and prison drug. It has attracted unscrupulous doctors and caused more health problems and deaths than its advocates acknowledge. It has become a lucrative commodity, creating moneymaking opportunities for manufacturers, doctors, drug dealers and even patients that have undermined an innovation meant for social good. Intended as a long-term treatment for people addicted to opioids — heroin as well as painkillers — buprenorphine is an opioid itself that can produce euphoria and cause dependency.

Comments are closed.


You have Free articles left this month.

Want access to all our reporting? Subscribe for unlimited access or login.